SK282945B6 - Perorálny prípravok na prevenciu a liečbu infekčných gastroenteritíd prasiat - Google Patents
Perorálny prípravok na prevenciu a liečbu infekčných gastroenteritíd prasiat Download PDFInfo
- Publication number
- SK282945B6 SK282945B6 SK237-99A SK23799A SK282945B6 SK 282945 B6 SK282945 B6 SK 282945B6 SK 23799 A SK23799 A SK 23799A SK 282945 B6 SK282945 B6 SK 282945B6
- Authority
- SK
- Slovakia
- Prior art keywords
- capm
- strains
- porcine
- antibodies
- bacteria
- Prior art date
Links
- 230000002265 prevention Effects 0.000 title claims abstract description 7
- 208000015181 infectious disease Diseases 0.000 title claims description 14
- 238000002560 therapeutic procedure Methods 0.000 title abstract description 3
- 239000013588 oral product Substances 0.000 title abstract 2
- 229940023486 oral product Drugs 0.000 title abstract 2
- 241000894006 Bacteria Species 0.000 claims abstract description 18
- 230000000369 enteropathogenic effect Effects 0.000 claims abstract description 9
- 241000702665 Porcine rotavirus Species 0.000 claims abstract description 8
- 210000002969 egg yolk Anatomy 0.000 claims abstract description 8
- 241000711573 Coronaviridae Species 0.000 claims abstract description 7
- 235000013345 egg yolk Nutrition 0.000 claims abstract description 7
- 241000193464 Clostridium sp. Species 0.000 claims abstract description 6
- 241000194031 Enterococcus faecium Species 0.000 claims abstract description 6
- 241000588724 Escherichia coli Species 0.000 claims abstract description 6
- 244000199866 Lactobacillus casei Species 0.000 claims abstract description 6
- 235000013958 Lactobacillus casei Nutrition 0.000 claims abstract description 6
- 240000006024 Lactobacillus plantarum Species 0.000 claims abstract description 6
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims abstract description 6
- 241000607149 Salmonella sp. Species 0.000 claims abstract description 6
- 229940017800 lactobacillus casei Drugs 0.000 claims abstract description 6
- 229940072205 lactobacillus plantarum Drugs 0.000 claims abstract description 6
- 238000004108 freeze drying Methods 0.000 claims abstract description 5
- 238000004519 manufacturing process Methods 0.000 claims abstract description 5
- 241000295636 Cryptosporidium sp. Species 0.000 claims abstract 3
- 241000955225 Isospora sp. Species 0.000 claims abstract 3
- 239000000203 mixture Substances 0.000 claims description 35
- 241000282887 Suidae Species 0.000 claims description 20
- 238000009472 formulation Methods 0.000 claims description 17
- 238000002360 preparation method Methods 0.000 claims description 17
- 208000005577 Gastroenteritis Diseases 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 11
- 239000000427 antigen Substances 0.000 claims description 8
- 102000036639 antigens Human genes 0.000 claims description 8
- 108091007433 antigens Proteins 0.000 claims description 8
- 239000006041 probiotic Substances 0.000 claims description 8
- 235000018291 probiotics Nutrition 0.000 claims description 8
- 235000013601 eggs Nutrition 0.000 claims description 7
- 230000002458 infectious effect Effects 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 7
- 231100000249 enterotoxic Toxicity 0.000 claims description 6
- 230000002242 enterotoxic effect Effects 0.000 claims description 6
- 230000000529 probiotic effect Effects 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- 241001148534 Brachyspira Species 0.000 claims description 5
- 239000000969 carrier Substances 0.000 claims description 5
- 229930003231 vitamin Natural products 0.000 claims description 5
- 239000011782 vitamin Substances 0.000 claims description 5
- 235000013343 vitamin Nutrition 0.000 claims description 5
- 229940088594 vitamin Drugs 0.000 claims description 5
- 235000019155 vitamin A Nutrition 0.000 claims description 5
- 239000011719 vitamin A Substances 0.000 claims description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 4
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 4
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 4
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 4
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 claims description 4
- 235000013305 food Nutrition 0.000 claims description 4
- 238000011282 treatment Methods 0.000 claims description 4
- 229940045997 vitamin a Drugs 0.000 claims description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- 229930006000 Sucrose Natural products 0.000 claims description 3
- 239000005862 Whey Substances 0.000 claims description 3
- 102000007544 Whey Proteins Human genes 0.000 claims description 3
- 108010046377 Whey Proteins Proteins 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- 235000013336 milk Nutrition 0.000 claims description 3
- 239000008267 milk Substances 0.000 claims description 3
- 210000004080 milk Anatomy 0.000 claims description 3
- 239000000600 sorbitol Substances 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- 229930003427 Vitamin E Natural products 0.000 claims description 2
- 230000004520 agglutination Effects 0.000 claims description 2
- 239000012530 fluid Substances 0.000 claims description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 2
- 238000001556 precipitation Methods 0.000 claims description 2
- 235000019165 vitamin E Nutrition 0.000 claims description 2
- 229940046009 vitamin E Drugs 0.000 claims description 2
- 239000011709 vitamin E Substances 0.000 claims description 2
- 230000000844 anti-bacterial effect Effects 0.000 claims 1
- 230000000840 anti-viral effect Effects 0.000 claims 1
- 238000001694 spray drying Methods 0.000 claims 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 abstract description 9
- 238000002156 mixing Methods 0.000 abstract description 4
- 239000000047 product Substances 0.000 abstract description 3
- 239000000546 pharmaceutical excipient Substances 0.000 abstract description 2
- 206010017964 Gastrointestinal infection Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000000688 enterotoxigenic effect Effects 0.000 abstract 1
- 238000004321 preservation Methods 0.000 abstract 1
- 238000000926 separation method Methods 0.000 abstract 1
- 241000894007 species Species 0.000 abstract 1
- 239000012141 concentrate Substances 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 7
- 238000009395 breeding Methods 0.000 description 6
- 230000001488 breeding effect Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000003242 anti bacterial agent Substances 0.000 description 5
- 229940088710 antibiotic agent Drugs 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 231100000676 disease causative agent Toxicity 0.000 description 5
- 244000005700 microbiome Species 0.000 description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- 238000002255 vaccination Methods 0.000 description 4
- 230000012010 growth Effects 0.000 description 3
- 244000005709 gut microbiome Species 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 230000003472 neutralizing effect Effects 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 206010003504 Aspiration Diseases 0.000 description 2
- 241000223935 Cryptosporidium Species 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 241000194033 Enterococcus Species 0.000 description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 208000010643 digestive system disease Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 230000005714 functional activity Effects 0.000 description 2
- 208000018685 gastrointestinal system disease Diseases 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 229940039696 lactobacillus Drugs 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 230000000384 rearing effect Effects 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 235000019195 vitamin supplement Nutrition 0.000 description 2
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 239000002028 Biomass Substances 0.000 description 1
- 241000510930 Brachyspira pilosicoli Species 0.000 description 1
- 241000193468 Clostridium perfringens Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000209630 Cystoisospora suis Species 0.000 description 1
- 206010012742 Diarrhoea infectious Diseases 0.000 description 1
- 241001148567 Lawsonia intracellularis Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000037006 agalactosis Effects 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000002953 anti-rotaviral effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000003022 colostrum Anatomy 0.000 description 1
- 235000021277 colostrum Nutrition 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000002577 cryoprotective agent Substances 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 208000037902 enteropathy Diseases 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000009969 flowable effect Effects 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 230000000521 hyperimmunizing effect Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000007542 postnatal development Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000009117 preventive therapy Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 239000000310 rehydration solution Substances 0.000 description 1
- 238000005067 remediation Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000002333 serotherapy Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 238000003307 slaughter Methods 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/02—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from eggs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CZ1998859A CZ287989B6 (cs) | 1998-03-20 | 1998-03-20 | Perorální přípravek k prevenci a léčbě infekčních gastroenteritid prasat |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SK23799A3 SK23799A3 (en) | 1999-10-08 |
| SK282945B6 true SK282945B6 (sk) | 2003-01-09 |
Family
ID=5462362
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK237-99A SK282945B6 (sk) | 1998-03-20 | 1999-02-24 | Perorálny prípravok na prevenciu a liečbu infekčných gastroenteritíd prasiat |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP0955061A1 (cs) |
| CZ (1) | CZ287989B6 (cs) |
| PL (1) | PL191391B1 (cs) |
| SK (1) | SK282945B6 (cs) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100437497B1 (ko) * | 2001-03-07 | 2004-06-25 | 주식회사 프로바이오닉 | 로타바이러스 및 유해 미생물 억제 활성을 가지는 신규내산성 락토바실러스 루테리 프로바이오-16 및 이를함유하는 생균활성제 |
| KR100542483B1 (ko) * | 2001-11-30 | 2006-01-16 | 주식회사 에그 바이오택 | 유아설사의 발병원인체인 대장균, 로타바이러스,아스트로바이러스에 대한 복합특수면역단백질을 함유한계란생산방법과 상기 계란에서 분리한복합특수면역단백질을 함유한 난황분말, 조제분유 |
| KR100471116B1 (ko) * | 2001-12-12 | 2005-03-08 | 주식회사 단바이오텍 | 장독성 대장균 감염의 예방 및 치료에 유용한 수용성단백질 및 이를 포함한 알 및 이들의 제조 방법 |
| EP1476184A4 (en) * | 2001-12-28 | 2006-01-04 | Camas Inc | IMMUNOGENOUS LIABILITY AND METHOD FOR ITS MANUFACTURE AND USE |
| KR100585391B1 (ko) * | 2002-01-24 | 2006-06-01 | 주식회사 프로바이오닉 | 돼지 전염성위장염 (TGE) 코로나바이러스 및 유해 미생물 억제 활성을 갖는 신규 락토바실러스 프란타럼 Probio-38 및 이를 함유하는 생균활성제 |
| KR100585392B1 (ko) * | 2002-01-24 | 2006-05-30 | 주식회사 프로바이오닉 | 돼지 전염성위장염 (TGE) 코로나바이러스 및 유해 미생물 억제 활성을 갖는 신규 락토바실러스 살리바리우스 Probio-37 및 이를 함유하는 생균활성제 |
| KR100492492B1 (ko) * | 2002-03-07 | 2005-05-31 | 주식회사 에그 바이오택 | 대장균(k88), 대장균(k99), 유행성설사병바이러스, 전염성위장염바이러스에 대한 복합특수면역단백질을 함유한 계란을 생산하는 방법 및 상기 방법으로 생산한 계란 |
| CA2404356A1 (en) * | 2002-09-18 | 2004-03-18 | Canadian Inovatech Inc. | Gram-positive antibacterial composition and method for use |
| CA2541753A1 (en) * | 2003-07-10 | 2005-01-20 | Michelle Alfa | Combination therapy for gastroenteric diseases caused by microorganisms |
| WO2005007834A1 (en) * | 2003-07-23 | 2005-01-27 | Probionic Corp. | Acid tolerant probiotic lactobacillus plantarum probio-38 that can suppress the growth of pathogenic microorganism and tge coronavirus |
| WO2005016383A1 (en) * | 2003-08-14 | 2005-02-24 | Merial Limited | Compositions and vaccines containing antigen(s) of cryptosporidium parvum and of another pathogen |
| JP2010531149A (ja) * | 2007-06-28 | 2010-09-24 | セーホーエル．ハンセン アクティーゼルスカブ | 細胞懸濁液の処理 |
| WO2011036539A1 (en) * | 2009-09-23 | 2011-03-31 | Borody Thomas J | Therapy for enteric infections |
| GB2484126A (en) | 2010-09-30 | 2012-04-04 | Univ Plymouth | Foodstuff fermented with lactic acid producing bacteria |
| DE102011006781A1 (de) * | 2011-04-05 | 2012-10-11 | Mat-Malta Advanced Technologies Limited | Antikörperprodukt, umfassend n spezifische Antikörper |
| DE102011006809A1 (de) | 2011-04-05 | 2012-10-11 | Freistaat Bayern vertreten durch die Julius-Maximilians-Universität Würzburg | Verwendung eines Mittels aus Antikörpern und/oder Insulin-like growth factor-Antagonisten |
| KR101353084B1 (ko) * | 2011-12-30 | 2014-01-17 | 대한민국 | 가금분변에서 분리한 항생제저항성 포도상구균과 살모넬라를 억제하는 신규유산균 락토바실러스 살리바리우스 |
| AR115757A1 (es) * | 2018-07-13 | 2021-02-24 | Cj Cheiljedang Corp | Composición que comprende la cepa cjlp475 de lactobacillus plantarum y la cepa cjlp17 de lactobacillus plantarum y el uso de la misma |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0706400A1 (en) * | 1993-03-15 | 1996-04-17 | Pharma Pacific Pty. Ltd. | Therapeutic formulation and method |
| JPH10298105A (ja) * | 1997-04-23 | 1998-11-10 | Gen Corp:Kk | 腸管出血性大腸菌による感染症の予防剤および治療剤 |
| CZ287956B6 (cs) * | 1997-11-04 | 2001-03-14 | Medipharm Cz, S. R. O. | Perorální přípravek k prevenci a léčbě parvovirózy psů |
-
1998
- 1998-03-20 CZ CZ1998859A patent/CZ287989B6/cs not_active IP Right Cessation
-
1999
- 1999-02-16 EP EP99301120A patent/EP0955061A1/en not_active Ceased
- 1999-02-24 SK SK237-99A patent/SK282945B6/sk not_active IP Right Cessation
- 1999-03-20 PL PL332146A patent/PL191391B1/pl unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SK23799A3 (en) | 1999-10-08 |
| PL332146A1 (en) | 1999-09-27 |
| CZ85998A3 (cs) | 1998-10-14 |
| EP0955061A1 (en) | 1999-11-10 |
| PL191391B1 (pl) | 2006-05-31 |
| CZ287989B6 (cs) | 2001-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SK282945B6 (sk) | Perorálny prípravok na prevenciu a liečbu infekčných gastroenteritíd prasiat | |
| Gharib et al. | Comparison of the effects of probiotic, organic acid and medicinal plant on Campylobacter jejuni challenged broiler chickens | |
| Quigley Iii et al. | Effects of oral antibiotics or bovine plasma on survival, health and growth in dairy calves challenged with Escherichia coli | |
| BR112020022085A2 (pt) | lactobacillus plantarum cjlp17 que apresenta eficácias antiviral e imunomodulatória e composição que compreende o mesmo | |
| Murayama et al. | Effects of orally administered Clostridium butyricum MIYAIRI 588 on mucosal immunity in mice | |
| SK283072B6 (sk) | Perorálny prípravok na prevenciu a liečbu parvovirózy psov a spôsob jeho výroby | |
| Prudyus et al. | Morphological changes in the immune system organs of piglets fed with different feed additives. | |
| WO2021087441A2 (en) | Composition and methods for preventing and treating african swine fever in wild and domestic swine | |
| JP4073922B2 (ja) | ビフィズス菌増殖促進成分を含有する飼料組成物とその使用方法 | |
| CN108371247A (zh) | 一种提高仔猪存活率的复合益生菌 | |
| JP6918144B2 (ja) | ラクトバチルス・プランタルムｃｊｌｐ４７５菌株とラクトバチルス・プランタルムｃｊｌｐ２４３菌株とを含む組成物及びその用途 | |
| EP0930316B1 (en) | Oral product for the prevention and treatment of infectious gastroenteritides in calves | |
| CN104721443B (zh) | 一种用于防治仔猪腹泻的中药复方制剂及其制备方法 | |
| KR100956648B1 (ko) | 돼지질병의 항원 제조방법 및 면역 난황항체 생산과전해질을 첨가한 돼지질병 방제용 조성물 | |
| TW200423950A (en) | Antidiarrheal composition | |
| CN109122551B (zh) | 一种防猪球虫病的养猪方法 | |
| CN1178703A (zh) | 幼儿胃肠安制剂及其生产工艺 | |
| KR100492492B1 (ko) | 대장균(k88), 대장균(k99), 유행성설사병바이러스, 전염성위장염바이러스에 대한 복합특수면역단백질을 함유한 계란을 생산하는 방법 및 상기 방법으로 생산한 계란 | |
| RU2471359C1 (ru) | Способ коррекции иммунобиологических показателей у поросят в период отъема | |
| US6296879B1 (en) | Ruminal fluid inoculation of calves | |
| Carvajal et al. | Efecto de la administración oral de microorganismos eficientes en los indicadores productivos, síndrome diarreico y hemograma en cerdos lactantes | |
| Karamzadeh-Dehaghani et al. | The international journal of animal biosciences | |
| JP2021193979A (ja) | 家畜の初乳品質改善剤及び方法 | |
| Fahmy | PERFORMANCE OF BROILERS SUPPLEMENTED WITH A MICROBIAL PREPARATIONS | |
| CN108478791A (zh) | 抗仔猪pedv腹泻的药物组合物及其制备方法与应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Patent lapsed due to non-payment of maintenance fees |
Effective date: 20160224 |